Ozempic and Rybelsus:
Ozempic:
Wegovy:
Contraindicated in:
Use Cautiously in:
CV: ↑ heart rate.
Derm: hair loss.
EENT: retinopathy complications.
Endo: hypoglycemia, MEDULLARY THYROID CARCINOMA.
GI: abdominal pain, constipation, diarrhea, nausea, vomiting, ↓ appetite, ↑ amylase, ↑ lipase, abdominal distention, cholecystitis, cholelithiasis, dyspepsia, flatulence, PANCREATITIS, vomiting.
GU: acute kidney injury.
Local: injection site reactions.
Neuro: fatigue, headache, dizziness, SUICIDAL BEHAVIOR/IDEATION (WEGOVY ONLY).
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
Type 2 Diabetes
Reduction in Risk of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease
Chronic Weight Management
Absorption: 89% absorbed following SUBQ injection; 0.41% absorbed following oral administration.
Distribution: Minimally distributed to tissues.
Protein Binding: >99%.
Metabolism/Excretion: Endogenously metabolized; eliminated in the urine (3% as unchanged drug) and feces.
Half-life: 1 wk.
NDC Code*